Active, not recruitingPhase 3NCT03905707

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Zealand Pharma
Principal Investigator: Zealand Pharma
Zealand Pharma
Intervention: glepaglutide(drug)
Enrollment: 145 enrolled
Eligibility: 18-90 years · All sexes
Timeline: 2019 – 2026

Study locations (27)

Georgetown University Medical Center, Washington D.C., District of Columbia, United States
University of Chicago Children's Hospital, Chicago, Illinois, United States
Mayo Clinic College of Medicine, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Mount Sinai Hospital, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
Vanderbilt University Medical Center, Nashville, Nashville, Tennessee, United States
UZ Leuven, Leuven, Belgium
The Royal Alexandra Hospital, Edmonton, Canada
Western University, London, Canada
University Health Network - Toronto General Hospital, Toronto, Canada
Rigshospitalet, Copenhagen, Denmark
Hôpital Beaujon, Clichy, France
Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
Charité - Universitätsmedizin Berlin, Berlin, Germany
+12 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03905707 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials